Navigation Links
Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival

and thrombocytopenia (each 3%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to c
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:10/9/2008)...Call/ -- Diamyd Medical reports,that the world,s m...ournal,of Medicine, has published an article with ...diabetes vaccine for type 1 diabetes., (Logo: ht... ), The article is now available on the journal,s...rint on October 30. It presents the,results of the...
(Date:10/8/2008)...osmetics and Chemicals Testing, ASHLAND, Mass., O...,that results of a recently completed US and Europ...n MatTek,s EpiDerm in vitro human skin tissue,equi... sensitivity and,specificity for EpiDerm to be acc... for determining human skin irritation by the Euro...
(Date:10/8/2008)...rch That May Offer New Hope to,Heart Failure Patie...over 3,000 people are,waiting for a heart transpla...those will receive a transplant. Now, pioneering r... the way for how to treat congestive heart,failure...ease, go to:, http://www.prnewswire.com/mnr/ahi/35...
(Date:10/8/2008)...xpand Testing Using Cellular .... 8 /- Wild Blueberry antioxidant,res...rom a new study,showing Wild Blueberries outperfor...ples, bananas, red grapes and strawberries in an e...ty (CAA) assay. New research,published in the curr...
Breaking Medicine Technology:Diamyd(R) Study Published in Prestigious New England Journal of Medicine 2Diamyd(R) Study Published in Prestigious New England Journal of Medicine 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 4MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3UT Southwestern urologist uses Botox to treat debilitating condition 7591 1UT Southwestern urologist uses Botox to treat debilitating condition 7591 2Good Clean Foods New Line of All Natural Simmer Sauces for Chicken Hits Market Shelves 7589 1Good Clean Foods New Line of All Natural Simmer Sauces for Chicken Hits Market Shelves 7589 2Good Clean Foods New Line of All Natural Simmer Sauces for Chicken Hits Market Shelves 7589 3Rising food prices threaten worlds poor people 1461 1Rising food prices threaten worlds poor people 1461 2Rising food prices threaten worlds poor people 1461 3Rising food prices threaten worlds poor people 1461 4Heska to Present at New York Society of Security Analysts Biotech Specialty Pharma Conference 7586 1
...School and Daycare Study Outcomes Suggest,Vaccin...or,Community at Large, TORONTO, May 08, 2007 /...ed today research results showing that use of FluM...) in daycare and school,settings may help reduce...yses applied to outcomes observed in previously co...
...USINESS WIRE)--May 9, 2007 - Regeneron,Pharmaceuti...,results from several studies evaluating the VEGF ...cular degeneration (wet AMD) and,diabetic macular ...ek at the annual meeting of the Association for Re...a reported at the meeting,from a pre-planned inter...
Other Medicine Technology:Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 2Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 3Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 4Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 5Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 6Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 7Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 8VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 2VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 3VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 4VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 5
(Date:10/10/2008)...OBI, Kenya, Oct. 10 /PRNewswire-USNewswire/ -- Pub...a global meeting convened to make,decisions on the...ronment.,On 6-10 October 2008, the 2nd UNEP(2) Ope... the elements that would form part of a global fra...erning Council (GC) in February,2009, where it wil...
(Date:10/10/2008)... The Healthcare Technology Evolu... Exton, PA (PRWEB) Septemb...Chapters of the national Healthcare Information Ma...ces to bring regional health information technolog...nference entitled The Healthcare Technology Evolut...
(Date:10/10/2008)... YORK, Oct. 10 /PRNewswire/ -- The Johns Hopkins U...multimedia educational program,"Optimizing Adjuva...eatment,Selection," to present recent key research...tment., In recent years, advancements in the trea...c and biologic treatment combinations that are,inc...
(Date:10/9/2008)...ding Melanoma Specialists Will Give Accredited Cou...agement of Melanoma, To be held November 1, 2008 ... CONCORD, Mass., Oct. 9 /PRNewswire-USNewswire/ --...ston University School of Medicine are,co-sponsori... Education,(ACCME) course to update non-dermatolog...
Breaking Medicine News(10 mins):Health News:Elements for a UN Global Framework on Mercury Agreed to 2Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Paul Sullivan's Legacy: An Early Warning Program for Detecting Melanoma Before It's Too Late 2
...s of Indian origin obtained an unprecedented emerg... down by the Department of Health. The new law pot...veral non-European doctors in the current round of...rvice (NHS). The injunction has been obtained aga...
...a government has planned to introduce an amendment...mpler for mentally ill patients to be committed to...ications. This proposed legislation was received ...rters of the society. While the advocates of the m...
...tralian Fashion Week activities commence around th...nment to work with the fashion industry and health...l the body image promoted by fashion models. Such...lf esteem and poor health among people who are inf...
...dition of immunotherapy to chemotherapy for malign...urvival rates, researchers have //found, and patie..., when the two treatments are combined. Malignant...n the cells responsible for skin color, and is one...
Other Medicine News:Health News:UK Indian Doctors Obtain Injunction Against New Rule 2Health News:Immunotherapy Does Not Prolong Life When Skin Cancer Spreads 2Health News:Immunotherapy Does Not Prolong Life When Skin Cancer Spreads 3
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: